Clinical Outcomes of MLC601 (NeuroAiD
MLC601
clinical outcome
nonsurgical lesion
traumatic brain injury
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
21 Jan 2020
21 Jan 2020
Historique:
received:
19
12
2019
revised:
31
12
2019
accepted:
16
01
2020
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
25
1
2020
Statut:
epublish
Résumé
MLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of MLC601 in treating TBI. This Indonesian pilot study aimed to investigate clinical outcomes of MLC601 for TBI. This randomized controlled trial included subjects with nonsurgical moderate TBI allocated into two groups: with and without MLC601 over three months in addition to standard TBI treatment. Clinical outcomes were measured by the Glasgow Outcome Scale (GOS) and Barthel Index (BI) observed upon discharge and at months (M) 3 and 6. Thirty-two subjects were included. The MLC601 group ( In this cohort of nonsurgical moderate TBI subjects, MLC601 showed potential for a positive effect on clinical outcome with no adverse effects.
Sections du résumé
BACKGROUND
BACKGROUND
MLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of MLC601 in treating TBI. This Indonesian pilot study aimed to investigate clinical outcomes of MLC601 for TBI.
METHODS
METHODS
This randomized controlled trial included subjects with nonsurgical moderate TBI allocated into two groups: with and without MLC601 over three months in addition to standard TBI treatment. Clinical outcomes were measured by the Glasgow Outcome Scale (GOS) and Barthel Index (BI) observed upon discharge and at months (M) 3 and 6.
RESULTS
RESULTS
Thirty-two subjects were included. The MLC601 group (
CONCLUSION
CONCLUSIONS
In this cohort of nonsurgical moderate TBI subjects, MLC601 showed potential for a positive effect on clinical outcome with no adverse effects.
Identifiants
pubmed: 31973204
pii: brainsci10020060
doi: 10.3390/brainsci10020060
pmc: PMC7071378
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The study was designed and conducted independently by the research team. The authors declare no financial or other conflicts of interest. All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Stroke. 2009 Mar;40(3):859-63
pubmed: 19164787
Epilepsia. 2003;44(s10):2-10
pubmed: 14511388
Neurosurgery. 1992 Nov;31(5):975-8
pubmed: 1436429
Lancet Neurol. 2008 Aug;7(8):728-41
pubmed: 18635021
Neuroscience. 2014 Sep 26;277:72-86
pubmed: 24993477
Eur J Neurol. 2018 Aug;25(8):1055-e82
pubmed: 29611892
Stroke Res Treat. 2011;2011:721613
pubmed: 21776364
J Neurotrauma. 2005 Sep;22(9):947-54
pubmed: 16156710
Neuropharmacology. 2011 Sep;61(4):622-31
pubmed: 21605573
Neuropharmacology. 2010 Jun;58(7):987-1001
pubmed: 20064536
Eur J Intern Med. 2011 Oct;22(5):509-13
pubmed: 21925062
Arch Phys Med Rehabil. 2008 Dec;89(12 Suppl):S69-76
pubmed: 19081444
Cerebrovasc Dis. 2010;30(1):1-6
pubmed: 20395679
Cerebrovasc Dis. 2015;39(5-6):309-18
pubmed: 25925713
J Neuroimmune Pharmacol. 2015 Mar;10(1):45-54
pubmed: 25331680
Cerebrovasc Dis. 2013;35 Suppl 1:1-7
pubmed: 23548913